THE DEAL, AT A GLANCE

Oxford spinout Alethio

From the announcement

Medicine development

What it doesENDS About Alethio Therapeutics A spin-out from the University of Oxford, Alethio Therapeutics is pioneering the development of targeted therapies with disease-modifying…From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗

02Who is involvedBacked by Sofinnova Partners, RA Capital, University of Oxford, Cancer Research HorizonsFrom the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗

03What happenedOxford spinout Alethio raised Series A, announced 2026-11-05From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗

04Why it mattersAlethio Therapeutics raised a $90M Series A to advance its G6B-targeting antibody ATX-011 into clinical trials for essential thrombocythemia.From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗

Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗

Oxford spinout Alethio · Financing Record

Explore source-linked visual explanations for Oxford spinout Alethio. Unsupported claims are withheld while source review continues.

Record 15379 · Recorded date: 2026-11-05

What it does

Alethio: illustrative category image — Illustrative image (biotech lab), not Alethio's product · Stephane Lesbats (IFREMER, Pôle Images, Centre Bretagne - ZI / CC BY 4.0

Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.

Open record 15379 →

Explore company records →